Display options
Cite
Shin SJ, Lee KH, Chung KS, et al. The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis. Exp Ther Med. 2017;13(3):1025-1031doi: 10.3892/etm.2017.4088.
Shin, S. J., Lee, K. H., Chung, K. S., Cheon, S. Y., & An, H. J. (2017). The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis. Experimental and therapeutic medicine, 13(3), 1025-1031. https://doi.org/10.3892/etm.2017.4088
Shin, Su-Jin, et al. "The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis." Experimental and therapeutic medicine vol. 13,3 (2017): 1025-1031. doi: https://doi.org/10.3892/etm.2017.4088
Shin SJ, Lee KH, Chung KS, Cheon SY, An HJ. The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis. Exp Ther Med. 2017 Mar;13(3):1025-1031. doi: 10.3892/etm.2017.4088. Epub 2017 Jan 25. PMID: 28450936; PMCID: PMC5403478.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 Mar;13(3):1025-1031. doi: 10.3892/etm.2017.4088. Epub 2017 Jan 25.

The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis.

Experimental and therapeutic medicine

Su-Jin Shin, Kwang-Ho Lee, Kyung-Sook Chung, Se-Yun Cheon, Hyo-Jin An

Affiliations

  1. Department of Pharmacology, College of Korean Medicine, Sangji University, Wonju, Gangwon 26339, Republic of Korea.
  2. Department of Acupuncture and Moxibustion Medicine, College of Korean Medicine, Sangji University, Wonju, Gangwon 26339, Republic of Korea.

PMID: 28450936 PMCID: PMC5403478 DOI: 10.3892/etm.2017.4088

Abstract

Benign prostatic hyperplasia (BPH) is a pathological condition that affects the majority of men above the age of 50 years. Pharmacological agents are typically used to treat BPH; however, there are currently no pharmacological agents that are able to completely cure BPH without causing adverse side effects. As a result of these side effects, there is a great interest in developing effective herbal medicines that are able to inhibit the progression of BPH and are safe for long-term use. Ga-Gam-Nai-Go-Hyan (GGN) is a traditional Korean herbal medicine that has been widely used to treat BPH; however, no biological studies have been performed to elucidate the efficacy of GGN. The aim of the present study was to evaluate the efficacy of GGN as a treatment for BPH. GGN administration was demonstrated to significantly decrease prostate weight (P<0.001), the relative prostate weight ratio (P<0.001) and the ratio of prostate weight to body weight (P<0.001). In addition, GGN treatment was revealed to suppress testosterone and dihydrotestosterone serum levels (P<0.001) and the growth of prostatic tissue. GGN also decreased the levels of the two inflammatory proteins (P<0.05), inducible nitric oxide synthase and cyclooxygenase-2, decreased the levels of the two apoptotic suppressors (P<0.05) B-cell lymphoma (Bcl)-2 and Bcl-xL and increased the levels of the pro-apoptotic factors (P<0.05) Bcl-2-associated X protein, caspase-3, caspase-8, Fas, Fas ligand and Fas-associated protein with death domain. The results of the present study suggested that GGN may have suppressive effects on the development of BPH and therefore have the potential to be used for treating BPH.

Keywords: B-cell lymphoma 2; Ga-Gam-Nai-Go-Hyan; apoptosis; benign prostatic hyperplasia; inflammation

References

  1. Immunity. 2009 Feb 20;30(2):180-92 - PubMed
  2. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8 - PubMed
  3. J Sex Med. 2010 Jan;7(1 Pt 1):107-20 - PubMed
  4. Eur Urol. 2005 Jan;47(1):72-8; discussion 78-9 - PubMed
  5. J Urol. 2003 Apr;169(4):1520-5 - PubMed
  6. Korean J Physiol Pharmacol. 2015 Mar;19(2):183-9 - PubMed
  7. Differentiation. 2011 Nov-Dec;82(4-5):184-99 - PubMed
  8. Res Rep Urol. 2012 Dec 31;5:1-10 - PubMed
  9. Prostate. 2009 Dec 1;69(16):1774-80 - PubMed
  10. Prostate. 2004 Sep 15;61(1):60-72 - PubMed
  11. Pharmacol Res. 2015 Sep;99:1-10 - PubMed
  12. BJU Int. 2001 Jul;88(1):100-3 - PubMed
  13. Can J Physiol Pharmacol. 2016 Jan;94(1):104-11 - PubMed
  14. Mol Cell. 2003 Feb;11(2):529-41 - PubMed
  15. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402 - PubMed
  16. Rev Urol. 2011;13(3):147-50 - PubMed
  17. In Vivo. 2007 Jan-Feb;21(1):123-32 - PubMed
  18. Hum Pathol. 1996 Jul;27(7):668-75 - PubMed
  19. J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):254-60 - PubMed
  20. Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 - PubMed
  21. J Cell Biochem. 2015 Jul;116(7):1286-99 - PubMed
  22. Biol Pharm Bull. 2004 Mar;27(3):333-7 - PubMed
  23. Eur Urol. 2007 Oct;52(4):964-72 - PubMed
  24. J Virol. 2007 Sep;81(17):9368-76 - PubMed
  25. Int J Androl. 2010 Jun 1;33(3):475-88 - PubMed
  26. Cell Cycle. 2008 Jul 1;7(13):1949-55 - PubMed
  27. Prostate. 2016 Nov;76(15):1431-44 - PubMed
  28. Nutr Cancer. 2013;65(3):505-14 - PubMed
  29. Can J Urol. 2006 Feb;13 Suppl 1:46-7 - PubMed
  30. Eur Urol. 1996;29 Suppl 2:3-9 - PubMed
  31. Eur Urol. 2000 Apr;37(4):367-80 - PubMed
  32. Cochrane Database Syst Rev. 2010 Oct 06;(10):CD006015 - PubMed
  33. Int Immunopharmacol. 2015 Sep;28(1):129-35 - PubMed
  34. Curr Pharm Biotechnol. 2013;14(3):261-73 - PubMed
  35. Eur Urol. 2011 Jul;60(1):106-17 - PubMed
  36. Eur Urol. 2013 Jul;64(1):118-40 - PubMed

Publication Types